Mailing address: emilio Antonio Francischetti • Rua Paulo César de Andrade, 106/602 22221-090 Rio de Janeiro, RJ Brazil E-mail: [email protected] Received on 04/18/06 • Accepted on 07/14/06 The prevalence of many cardiovascular risk factors has been significantly reduced in the last forty years1. Therapeutic advance gained from lipid-lowering agents, anti-hypertensive drugs, and anti-diabetic ora...

The cloning of estrogen receptors (ERs) and generation of ER-deficient mice have increased our understanding of the molecular mechanisms underlying the cardiovascular effects of estrogen. It is conceivable that clinical trials of estrogens so far failed to improve cardiovascular health because of the poor ER isoform selectivity and tissue specificity of endogenous hormones as well as incorrect ...

The diagnoses and subsequent treatment of poisoned patients manifesting cardiovascular compromise challenges the most experienced emergency physician. Numerous drugs and chemicals cause cardiac and vascular disorders. Despite widely varying indications for therapeutic use, many agents share a common cardiovascular pharmacologic effect if taken in overdose. Standard advanced cardiac life support...

The aim of the study was to determine cardiovascular drugs utilization and quality of prescribing in Croatia from 2003 to 2008. Data on the outpatient utilization of cardiovascular drugs in Croatia were collected during 2003-2008. Data on the size and number of packages, were obtained from Croatian institute for Health Insurance (CIHI). Based on the data obtained, the numbers of DDD and DDD per...

Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase (COX) enzymes, which exist in at least two isoforms, COX-1 and COX-2. Aspirin and older agents in this class are nonselective inhibitors of both COX-1 and COX-2. Newer agents termed "coxibs" are selective inhibitors of COX-2. Among the NSAID, only aspirin has been proven to significantly reduce cardiovascular risk, primarily th...

OBJECTIVES To summarize data supporting the effects of antidiabetes agents on glucose control and cardiovascular risk factors in patients with type 2 diabetes. METHODS Studies reporting on the effects of antidiabetes agents on glycemic control, body weight, lipid levels, and blood pressure parameters are reviewed and summarized for the purpose of selecting optimal therapeutic regimens for pat...

Safety concerns have been raised regarding possible association of major adverse cardiovascular events (MACEs) with use of anti-IL-12/23 biologic agents for the treatment of chronic plaque psoriasis (CPP). Ten MACEs have been recorded in actively-treated patients during the placebo-controlled phase of phase II and III studies compared with zero events in placebo-treated patients, along with a t...